Page last updated: 2024-12-10

farnesyl monophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID6440220
SCHEMBL ID2506806
MeSH IDM0164746

Synonyms (8)

Synonym
gtpl2911
farnesyl monophosphate
[(2z,6z)-3,7,11-trimethyldodeca-2,6,10-trienyl] dihydrogen phosphate
(2z,6z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl dihydrogen phosphate
FFT ,
2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, dihydrogen phosphate, (e,e)-
SCHEMBL2506806
Q27077282
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346181Human LPA3 receptor (Lysophospholipid (LPA) receptors)2009The Journal of biological chemistry, Jun-19, Volume: 284, Issue:25
Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
AID1345272Human LPA5 receptor (Lysophospholipid (LPA) receptors)2009The Journal of biological chemistry, Jun-19, Volume: 284, Issue:25
Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
AID1346181Human LPA3 receptor (Lysophospholipid (LPA) receptors)2006Biochimica et biophysica acta, Dec, Volume: 1761, Issue:12
Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs.
AID1346958Human LPA4 receptor (Lysophospholipid (LPA) receptors)2009The Journal of biological chemistry, Jun-19, Volume: 284, Issue:25
Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's5 (71.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]